Vaxil Bio Ltd. (TSXV:VXL)

Canada flag Canada · Delayed Price · Currency is CAD
0.2150
-0.0550 (-20.37%)
At close: May 23, 2025
-57.00%
Market Cap 671.20K
Revenue (ttm) n/a
Net Income (ttm) -190.00K
Shares Out 2.74M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,299
Average Volume 4,414
Open 0.2150
Previous Close 0.2700
Day's Range 0.2150 - 0.2150
52-Week Range 0.2000 - 0.2750
Beta -1.45
RSI 37.04
Earnings Date May 27, 2025

About Vaxil Bio

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. The company was founded in 2006 and is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol VXL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.